Loading
A phase 2 trial of Capecitabine, Oxaliplatin and Retlirafusp alfa in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05300269 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 73 participants planned, started 2022-07-05 and due to reach its primary completion in 2024-07-31. Interventions recorded: SHR-1701；Capecitabine；Oxaliplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Retlirafusp alfa, Oxaliplatin, Jiangsu Hengrui Pharmaceuticals, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Jiangsu Hengrui Pharmaceuticals, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.
Shares Retlirafusp alfa, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Rectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/